Ampio Pharmaceuticals has postponed a plot to spin out one of its subsidiaries through an IPO, citing unfavorable market conditions.
Amgen and AstraZeneca have racked up their third straight Phase III win for brodalumab in plaque psoriasis, beating J&J's Stelara in a head-to-head study. The news comes just two weeks after the pharma partners posted their latest positive results, positioning them for a run at regulators on both sides of the Atlantic.
Five years after the FDA formally rejected J&J's Yondelis (trabectedin) for ovarian cancer, and three years after an aborted effort to get it back on track, the pharma giant has finally made its way back to the agency for another try at an approval--this time as a treatment for soft tissue sarcoma.
Promethera Biosciences has put together €25.3 million ($31.4 million) in equity and loans to hit the gas on its stem cell treatment for rare liver diseases.
Will they or won't they? That question seems to be on quite a few minds these days as the oddsmakers assess the chances of another Pfizer megamerger bid for AstraZeneca after the U.K.'s cooling off period ends on Wednesday.
The FDA wants more time to deliberate on Novartis' panobinostat, a multiple myeloma treatment that failed to impress a panel of independent experts, signaling a delay that could nearly negate the agency's previous promise of a speedy review.
London's Cell Medica has raised a £50 million ($78 million) B round to support its work on treatments that train the body's immune system to fight cancer and infectious disease, rolling through midstage trials with an oncology candidate.
High-profile U.K. investor Neil Woodford made headlines last week when he invested $25 million into Northwest Biotherapeutics, and that's a sign of much more to come, according to reports, as the ex-Invesco manager is planning to unveil a new fund devoted solely to emerging biotechs.
Johnson & Johnson is following in the footsteps of pioneers like Novartis, Celgene and GlaxoSmithKline, inking a discovery-stage development deal--but turning to the little-known Transposagen Biopharmaceuticals to make its entry.
PRA Health Sciences and INC Research have both seen their shares tick upward since pulling off IPOs earlier this month, a sign that, despite biotech's boom and bust, the window for CRO debuts remains open.
Bristol-Myers Squibb has signed a deal with Five Prime Therapeutics to determine whether a combination of its star immuno-oncology contender and the biotech's antibody can make a difference in a range of cancers.
Amgen is calling off all clinical studies on rilotumumab in advanced gastric cancer after a peek at Phase III data revealed that the drug was actually making matters worse for patients, further marring the value of the company's oncology pipeline.
Polaris Partners, an ambitious venture investor that's been behind a legion of cutting-edge biotech startups, has come up with $450 million for its latest fund. The cash tops the $400 million mark that the VC had outlined in an SEC filing last summer, signaling another success for the year's blossoming class of new biotech venture funds.
Last year Lundbeck CEO Ulf Wiinberg got a "gift" of some shares in a biotech called Stratified Medical, a London-based company that bills itself as a partner that can help drug developers more efficiently develop new therapies. And after the gift arrived, Lundbeck invested 19 million Danish krone--a little more than $3 million--into the company.
Biotech upstart Juno Therapeutics has added an FDA "breakthrough" drug title to its considerable list of accomplishments, gaining regulators' commitment to hurry along a lead cancer program to a potential approval.
Merck has snapped up the exclusive rights to NewLink Genetics' Ebola vaccine, which is being rushed into a Phase III study as part of a global effort to head off an outbreak in West Africa.
BioMarin just bought itself a pricey ticket into a high-profile Phase III drug development race. The rare-disease specialist has stepped in to buy the Dutch biotech Prosensa for $680 million in cash while offering up to $160 million more in near-term milestones if it can land an early approval for its late-stage drug for Duchenne muscular dystrophy.
Thanks in part to its all-hands approach to immuno-oncology, AstraZeneca's pipeline is now nearly 50% biologics, leading the company to lay out $200 million to build the capacity it will need to follow through on those in-development projects.
San Diego's Neothetics, developer of a fat-busting treatment, came through on its plans to raise $65 million in an IPO, but, in keeping with a growing trend in biotech, watched its shares slide shortly after its debut.
The SEC has suspended the trading of a few microcap companies touting unverified Ebola treatments and tests, warning investors of penny stock peddlers looking to cash in on the West African outbreak that has killed thousands.